Thursday, 22 October 2026
Europe’s specialised laboratory and research property market is attracting greater attention from institutional investors seeking opportunities beyond conventional commercial real estate. However, differences in building specifications, tenant requirements and operating arrangements mean that investment risks can vary considerably between properties. A new study published by HELIX alpha examines these distinctions and identifies the factors investors should consider when evaluating facilities used by pharmaceutical, biotechnology and other research-intensive businesses.
The Hamburg-based investment and advisory platform released its research on 22 October 2026, examining how laboratory buildings and related scientific facilities can fit within institutional property portfolios. The analysis highlights the importance of understanding who finances specialist equipment, who manages the premises and how closely the financial performance of an investment depends on the activities of its occupiers. Unlike conventional office buildings, research properties frequently require substantial technical infrastructure and modifications tailored to particular scientific activities.
One approach involves property owners delivering buildings with the structural and essential technical systems needed to accommodate laboratory operations, while occupiers fund much of the specialised internal installation and scientific equipment. Such arrangements can provide investors with rental income supported by longer lease commitments, although the financial strength of the tenant and the adaptability of the property remain important considerations. At the other end of the market are facilities offering fully equipped laboratory accommodation together with operational services, allowing companies to access research infrastructure without making substantial initial investments in their own premises.
These different arrangements create distinct financial exposures. Properties occupied by established pharmaceutical or biotechnology companies under long-term agreements may offer relatively predictable rental income, depending on tenant creditworthiness and lease conditions. Facilities serving smaller research businesses can provide greater operational flexibility but may expose owners or specialist operators to higher management costs, changes in occupancy and the financial uncertainty associated with early-stage companies. Investors must therefore assess laboratory property according to its operating structure rather than treating the sector as a single investment category.
The technical characteristics of buildings are another important consideration. Research facilities can require advanced ventilation, specialist electrical systems, temperature controls, enhanced safety arrangements and infrastructure capable of supporting demanding scientific processes. These requirements can increase construction and refurbishment expenditure compared with conventional commercial premises. They may also create challenges when an existing tenant leaves, particularly if the building has been designed around highly specific activities that are difficult to accommodate for a replacement occupier.
Location is equally important, although successful research destinations do not necessarily correspond with Europe’s largest commercial property markets. Cities such as Heidelberg, Oxford and Leiden have developed recognised concentrations of universities, research institutions, pharmaceutical businesses and specialist service providers. These networks can generate demand for laboratory accommodation by bringing together scientific expertise, commercial funding and businesses engaged in research and development. For property investors, the strength of these local relationships can influence both occupancy prospects and the ability to secure replacement tenants.
The study also examines the potential stability associated with research occupiers that have invested heavily in adapting their premises. Relocating scientific operations can involve substantial expenditure, technical disruption and regulatory considerations, making certain businesses less inclined to move frequently. Nevertheless, such commitments do not eliminate investment risk. The financial position of the occupier, the remaining lease period and the property’s suitability for alternative users remain essential elements of assessing future income security.
HELIX alpha argues that Europe has opportunities to attract additional long-term investment into the buildings required to support scientific innovation. Although funding is available for research programmes and the development of biotechnology businesses, financing the specialised property infrastructure needed to accommodate these activities presents a separate challenge. Institutional investors could potentially contribute to meeting this requirement by providing capital for suitable laboratory and research facilities, provided the underlying property characteristics align with their investment objectives.
Martin Eberhardt FRICS, Founder and CEO of HELIX alpha, emphasises that investment decisions must distinguish between buildings leased to established businesses and facilities providing laboratory accommodation and services to emerging companies. The financial characteristics of these properties can differ substantially, particularly regarding operational responsibilities, tenant stability and the amount of capital required after acquisition.
Patrick Schlump, Managing Partner of HELIX alpha, similarly identifies the relationship between lease arrangements, occupier financial strength, technical expenditure and location quality as central to determining whether a property is appropriate for institutional investment. The research suggests that these considerations should be evaluated collectively, rather than relying on the broader growth prospects of the biotechnology and pharmaceutical industries.
For Europe’s commercial property sector, the findings highlight the potential for research-related facilities to develop into a more established specialist investment market. Demand for scientific accommodation is influenced by pharmaceutical research, biotechnology development and the expansion of innovation networks, but individual properties can have significantly different financial and operational characteristics. Investors entering the sector must therefore consider the technical requirements of laboratory buildings alongside the commercial fundamentals traditionally applied to income-producing real estate.
The study concludes that institutional participation could support the development and modernisation of Europe’s scientific property infrastructure. However, the investment case depends on selecting buildings with appropriate technical capabilities, financially sustainable occupiers and locations capable of maintaining demand over time. Rather than viewing laboratory accommodation as a uniform asset class, the research encourages investors to distinguish between different property and operating arrangements when assessing opportunities for long-term capital deployment.
